Stop paying for the waitlist
you already own.
Every member who slips backwards on the waitlist turns into a cost somewhere else — crisis presentations, readmission, lost treatment slots, longer programs at worse baselines. GKV pays for all of it. Kontexa START is being built to intervene at the cheapest possible point, on the regulatory path to a DiGA listing and a single PZN reimbursed via §33a SGB V. We are not listed yet. We are looking for payer partners to walk that path with us.
€250–500 vs.
a five-figure crisis cycle.
Once listed, a GKV-reimbursed DiGA prescription will cost less than one avoided emergency presentation. Even a modest reduction in waitlist backsliding would pay for the program many times over. The control condition for our validation study is the current standard of care — which is nothing. Whatever Kontexa delivers is incremental.
Reimbursed via §33a SGB V.
No new contracts. No new infrastructure.
The pathway below is the standard DiGA flow we are building toward. Steps 02 and 03 activate once Kontexa START is CE-marked and listed in the BfArM DiGA-Verzeichnis.
A physician or psychotherapist diagnoses an SUD and refers the member for therapy.
One PZN code on Muster 16. Thirty seconds at the desk. Member walks out with the program.
Standard DiGA reimbursement pathway. No bilateral contract required. No risk to the insurer beyond the unit cost.
A clinical asset
in an unclaimed category.
No other DiGA is designed around the addiction therapy waitlist. By engaging early, payers help shape the evidence base for a population that is effectively invisible to the system today.
- — Lower downstream cost per waitlist member
- — Measurable engagement and abstinence data
- — No IT integration on payer side
- — Category-shaping DiGA partnership, early